{'52WeekChange': 0.0050287247,
 'SandP52WeekChange': None,
 'address1': '1345 Avenue of Americas',
 'address2': '15th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.92,
 'askSize': 800,
 'averageDailyVolume10Day': 73362,
 'averageVolume': 87457,
 'averageVolume10days': 73362,
 'beta': 1.60112,
 'beta3Year': None,
 'bid': 13,
 'bidSize': 900,
 'bookValue': 2.331,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.98,
 'dayLow': 13.12,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.786,
 'enterpriseToRevenue': 932.856,
 'enterpriseValue': 271139168,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '347 679 8203',
 'fiftyDayAverage': 14.570286,
 'fiftyTwoWeekHigh': 18.99,
 'fiftyTwoWeekLow': 10.98,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 9712736,
 'forwardEps': -2.63,
 'forwardPE': -5.0874524,
 'fromCurrency': None,
 'fullTimeEmployees': 217,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.35514,
 'heldPercentInstitutions': 0.295,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1359590400,
 'lastSplitFactor': '1:100',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cellbiomedgroup.com',
 'longBusinessSummary': 'Cellular Biomedicine Group, Inc., a clinical stage '
                        'biopharmaceutical company, develops immunotherapies '
                        'for cancer and stem cell therapies for degenerative '
                        'diseases in Greater China. The company develops '
                        'treatments utilizing proprietary cell based '
                        'technologies, including immune cell therapy for '
                        'treating a range of cancer indications comprising '
                        'technologies in chimeric antigen receptor modified T '
                        'cells (CAR-T), T-cells with genetically modified, '
                        'tumor antigen-specific T-cell receptors, and next '
                        'generation neoantigen-reactive bio-markers based '
                        'tumor infiltrating lymphocytes; and human '
                        'adipose-derived mesenchymal progenitor cells for the '
                        "treatment of joint diseases The company's CAR-T "
                        'products include CD20 for use in anti-tumor '
                        'activities; CD22, a surface maker highly expressed in '
                        'B cell malignancies in hairy cell leukemia; and '
                        'B-cell maturation antigen therapies for treating '
                        'refractory multiple myeloma in patients. It also '
                        'develops NKG2D CAR therapies for use in NK cell '
                        'signaling; alpha fetoprotein TCR-T therapies for '
                        'treating hepatocellular carcinoma; tumor infiltrating '
                        'lymphocyte therapies for treating immunogenic '
                        'cancers; and knee osteoarthritis therapies, including '
                        'AlloJoin therapy, which is in a Phase II clinical '
                        'trial, as well as Re-Join that has completed the '
                        'Phase IIb clinical trial. In addition, it engages in '
                        'biopharmaceutical businesses, including research and '
                        'development, technical support, technical service, '
                        'and technology transfer activities in biomedical '
                        'technology field; manufacturing non-food, '
                        'pharmaceutical polypeptides, and medical devices; and '
                        'the wholesale of cosmetics, sanitary products, and '
                        'biological agents. The company has a collaboration '
                        'agreement with Novartis Pharma AG to manufacture and '
                        'supply their CAR-T cell therapy Kymriah in China. '
                        'Cellular Biomedicine Group, Inc. was incorporated in '
                        '2001 and is headquartered in New York, New York.',
 'longName': 'Cellular Biomedicine Group, Inc.',
 'market': 'us_market',
 'marketCap': 259455600,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_224236494',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -52194764,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.97,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '347 905 5663',
 'previousClose': 13.99,
 'priceHint': 2,
 'priceToBook': 5.7400255,
 'priceToSalesTrailing12Months': 892.6583,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.98,
 'regularMarketDayLow': 13.12,
 'regularMarketOpen': 13.97,
 'regularMarketPreviousClose': 13.99,
 'regularMarketPrice': 13.97,
 'regularMarketVolume': 54341,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 19391300,
 'sharesPercentSharesOut': 0.0275,
 'sharesShort': 532675,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 300241,
 'shortName': 'Cellular Biomedicine Group, Inc',
 'shortPercentOfFloat': 0.0361,
 'shortRatio': 6.49,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'CBMG',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.707,
 'twoHundredDayAverage': 15.234173,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '381b59a4-93b4-3f79-8617-b9d28b4daccd',
 'volume': 54341,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cellbiomedgroup.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10105'}